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Activating mutations in phosphatidylinositol 3-kinase (PI3K)-AKT pathway components 
cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (MPPH)1-3. 
We report that MPPH patients lacking upstream PI3K-AKT pathway mutations carry de 
novo mutations in cyclin D2 (CCND2), clustered around a residue that can be 
phosphorylated by glycogen synthase kinase 3Ś(GSK-3Ś)4. Mutant CCND2 was resistant to 
proteasomal degradation compared to wild type (WT) protein in vitro. The PI3K-AKT 
pathway modulates GSK-3Ś activity4 and accordingly, cells from patients with PIK3CA, 
PIK3R2 or AKT3 mutations similarly accumulated CCND2. CCND2 was expressed at 
higher levels in the brains of mouse embryos expressing activated Akt3. In utero 
electroporation of mutant CCND2 into the embryonic mouse brain produced more 
proliferating transfected progenitors and a smaller fraction exiting the cell cycle compared to 
cells electroporated with the WT sequence. These observations suggest that cyclin D2 
stabilization, due to CCND2 mutation or PI3K-AKT activation, provides a unifying 
mechanism in PI3K-AKT related megalencephaly syndromes.
Germline mutations of PIK3R2 and AKT3 result in MPPH3, while postzygotic mutations of 
PIK3CA cause megalencephaly-capillary malformation syndrome (MCAP)3, and 
postzygotic mutations of PIK3CA and AKT3 cause isolated hemimegalencephaly1,5. We 
previously failed to detect mutations in PIK3R2 or AKT3 in 35% of probands with MPPH3. 
We hypothesized that mutation-negative patients have de novo mutations in one or more 
novel genes, and performed whole exome sequencing in two child parent trios (JT-144, 
LR11-424) and one child-parent pair (LR02-064).
We identified germline mutations in CCND2 in all three patients (p.Thr280Ala in one and 
p.Lys270* in 2 unrelated subjects), confirmed to be de novo by Sanger sequencing. None of 
the identified variants were present in dbSNP build 132, the 1000 Genomes Project, the 
NHLBI exome variant server of 6500 exomes, or in-house exome databases (Online 
Methods). We identified de novo heterozygous CCND2 mutations in nine further MPPH 
patients by conventional Sanger sequencing. The clinical and molecular findings of this 
cohort are shown in Figure 1, and summarized in Table 1, and Supplementary Table 1.
All identified mutations affect highly conserved amino acid residues (Fig. 2 and 
Supplementary Fig.1). Notably, 9 of 12 involved p.Thr280 or p.Pro281 (Table 1). The 
p.Thr280Asn mutation occurred in 3 subjects while p.Lys270*, p.Thr280Ala, and 
p.Pro281Arg were found in 2 subjects each. Murine cyclin D2 can be phosphorylated on 
p.Thr280 in vitro by GSK-3Ś, rendering Ccnd2 susceptible to ubiquitin/proteasome-
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dependent degradation4. The p.Thr280Ala mutant cyclin D2 cannot be phosphorylated, does 
not become polyubiquitinated, and thus is resistant to degradation4. Interestingly, all 
mutations in our MPPH cohort either alter highly conserved residues surrounding p.Thr280, 
or truncate the protein prior to this phosphorylation site (p.Lys270X). As the latter mutation 
lies in the final exon, it is predicted not to induce nonsense-mediated mRNA decay.
To test whether mutations at particular residues in MPPH patients result in accumulation of 
degradation-resistant cyclin D2, we transfected HEK293 cells with either WT or mutant 
(p.Thr280Ala, p.Pro281Arg, p.Val284Gly, and p.Lys270*) human CCND2 myc-tagged 
constructs. Cells were treated with cycloheximide at 0.05 mg/ml 24 hours post-transfection 
to block protein translation, and protein extracts were analyzed by Western blotting (Fig. 
3a,b). A rapid reduction in cyclin D2 was seen in cells transfected with WT constructs 
following cycloheximide treatment. This was not observed in cells transfected with mutant 
constructs. Thus, MPPH-associated mutations in CCND2 result in accumulation of 
unphosphorylated degradation-resistant cyclin D2.
Activation of the PI3K-AKT pathway inhibits GSK-3Ś-mediated phosphorylation4. We 
hypothesized that the activating mutations previously observed in PIK3CA, PIK3R2, and 
AKT3 would also result in accumulation of degradation-resistant cyclin D2 through 
downstream inhibition of GSK-3Ś. Endogenous CCND2 levels were examined in 
lymphoblastoid cell lines derived from patients with mutations in PIK3CA (p.Glu453del), 
PIK3R2 (p.Gly373Arg), or AKT3 (p.Arg465Trp). Following cycloheximide treatment, we 
observed a decrease in CCND2 levels in control cells. In contrast, CCND2 in patient cells 
was resistant to degradation (Fig. 3c,d). These results suggest that megalencephaly-
associated mutations in components of the PI3K-AKT pathway share the same functional 
endpoint as the mutations observed in CCND2: namely inhibition of proteasomal 
degradation of cyclin D2.
The PI3K-AKT pathway inactivates GSK-3Ś by phosphorylation of the S9 residue6, which 
should interfere with GSK-3Ś dependent phosphorylation, ubiquitination, and proteasomal 
degradation of cyclin D2. Activating mutations previously described in PIK3R2 and 
PIK3CA result in activation of AKT33. To further test the relationship between cyclin D2 
and this pathway in vivo, we examined the levels of CCND2 in E14.5 embryonic cortex of 
mice homozygous for a gain-of-function Akt3D219V mutant allele7. Quantitative western blot 
analysis revealed a 30% increase in the pS9, inactive GSK-3Ś phosphoprotein, associated 
with a 30-40% increase in cyclin D2, equivalent to the increase in cyclin D1 (Fig. 3e).
Neocortical neurons and glia are generated in the embryonic ventricular and subventricular 
zones (VZ and SVZ)8. Cyclin D2 promotes neuronal progenitor commitment to undergo a 
round of division and progress through the cell cycle9-11. In embryonic mouse brain, Ccnd2 
is expressed in some VZ radial glial cells (RGCs) that co-label for Pax6, but primarily – 
though certainly not exclusively – Ccnd2- positive cells co-localize with Tbr2-positive 
intermediate progenitor cells (IPCs) in the SVZ12,13. IPCs are important drivers of brain 
size, since they allow for geometric expansion of cellular output from the SVZ10. Ccnd2 null 
mice display microcephaly and cerebellar hypoplasia14,15. In the human neocortex, CCND2 
is expressed more robustly than cyclin D1 by 19 gestational weeks15. Thus, elevated 
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CCND2 levels may enlarge brain size by maintaining cells in cycle and increasing 
progenitor numbers, while diminished CCND2 expression reduces brain volume by allowing 
cell cycle exit, resulting in progenitor pool depletion14.
We investigated the importance of CCND2 p.Thr280 and the neighboring p.Pro281 residue 
for VZ/SVZ divisions by testing mutations, including those found in MPPH patients, using 
in utero electroporation (IUEP) in mouse embryos (Online Methods). Western blot of 
HEK293 cells transfected with these constructs demonstrated that CCND2 sequences placed 
upstream of the IRES-eGFP cassette were actively translated into protein (Supplementary 
Fig. 2). Immunostaining of embryonic cortex following IUEP confirmed that expression of 
nuclear CCND2 in GFP-positive cells was elevated after transfection with mutant forms of 
CCND2 compared to cells transfected with GFP only or with untransfected cells (i.e. GFP-) 
(Supplementary Fig. 2).
IUEP was performed at embryonic day 13.5 (E13.5) and embryos were collected 48 hours 
later. Immunohistochemistry using anti-GFP and anti-Ki67 antibodies (Fig. 4) showed that 
85% of control cells expressing GFP alone did not co-label for Ki67, and therefore, had 
exited the cell cycle; a large proportion had migrated to the cortical plate (Fig. 4 a,f,k). 
Significantly more GFP-positive cells expressing WT cyclin D2 also co-labeled for Ki67 
and were actively dividing (27.6 ± 3.0% of GFP+ WT cyclin D2 vs. 14.6 ± 2.6% of GFP+ 
only controls) (Fig. 4 b,g,k). Electroporation of a mutant construct mimicking 
phosphorylation at Thr280 (p.Thr280Asp) (Fig. 4 d,i,k) yielded results statistically 
indistinguishable from the WT CCND2, suggesting that the transfected WT protein was 
near-maximally phosphorylated at residue 280. However, compared to the exogenous WT 
protein, cells expressing mutant CCND2 (p.Thr280Ala) had a significantly higher 
percentage of GFP+/Ki67+ co-labeled cells (54.9 ± 4.9% of GFP+ p.Thr280Ala vs. 27.6 ± 
3.0% of GFP+ WT cyclin D2 and 35.5 ± 5.3% GFP+ p.Thr280Asp) (Fig. 4 c,h,k). Another 
MPPH-mutation (p.Pro281Arg) also produced a higher percentage of proliferating GFP+ 
cells than the WT sequence (60.5 ± 4.2% GFP+ p.Pro281Arg vs. 27.6 ± 3.0% of GFP+ WT 
cyclin D2, 35.5 ± 5.3% GFP+ p.Thr280Asp) (Fig 4 e,j,k). The significance of these 
comparisons is summarized in Supplementary Table 2. These data support a mechanism in 
which aberrantly stabilized CCND2 mediates abnormal proliferation leading to increased 
neural progenitor numbers.
MPPH-associated CCND2 mutation effects on cell cycle function were investigated by 
determining the proportion of electroporated (GFP-positive) cells undergoing mitosis. We 
used immunodetection of phosphohistone H3 (PH3), a marker of cells in M-phase, 
following transfection with WT, phosphodeficient (p.Thr280Ala), and phosphomimetic 
(p.Thr280Asp) forms of CCND2. Electroporation of the WT CCND2 sequence resulted in 
2.83 ± 0.37% of GFP+ cells also being labeled for PH3, most of which were located within 
the VZ and SVZ (Fig. 5 a,d). The phosphodeficient CCND2 construct significantly 
increased cell numbers labeled for GFP and PH3 (Fig. 5 b,d) compared to the WT sequence 
(6.41 ± 0.22% p.Thr280Ala vs. 2.83 ± 0.37% WT CCND2, p=0.000054). Lastly, expression 
of the phosphomimetic sequence yielded a 3.39 ± 0.49% overlap between GFP and PH3-
immunoreactivity (Fig. 5 c,d), which was significantly different from the phosphodeficient, 
but not the WT CCND2, construct (Fig. 5d). Thus, the phosphodeficient form of CCND2 is 
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more effective in promoting mitosis compared to transfection with either the WT or 
phosphomimetic CCND2 sequences.
To examine the effect of WT and mutant CCND2 expression on cell cycle exit, 
bromodeoxyuridine (BrdU) was injected intraperitoneally into pregnant dams 24 hours post-
IUEP. After 24 hours tissues were collected and sections stained with anti-GFP, anti-BrdU, 
and anti-Ki67 antibodies to determine the proliferative fraction (P-fraction, ie: cells that 
remain in the cell cycle, GFP+/BrdU+/Ki67+) and exit fraction (ie: those cells that have 
exited the cell cycle 24 hours post-BrdU injection, GFP+/BrdU+/Ki67-). Following 
electroporation of the WT CCND2, 40.8 ± 4.4% of GFP+ cells were in the P-fraction, while 
59.2 ± 4.4% of cells accumulated in the exit fraction (Fig. 5e,h,k, Supplementary Table 3). 
After transfection with the phosphodeficient CCND2 mutation, progenitors displayed a 
higher P-fraction (59.3 ± 3.6%) and corresponding decrease in the exit fraction (40.7 ± 
3.6%) relative to the WT CCND2 sequence (Fig. 5e,f,h,i,k, Supplementary Table 3). The 
phosphomimetic CCND2 construct yielded P-fractions (45.4 ± 1.4%) and exit fractions 
(54.6 ± 1.4%) statistically identical to the WT CCND2 sequence (Fig. 5e,g,h,j,k, 
Supplementary Table 3). However, expression of the phosphomimetic CCND2 construct 
resulted in a lower P-fraction and higher exit fraction compared to the phosphodeficient 
CCND2 construct (Fig. 5f,g,i,j,k, Supplementary Table 3). Thus, expression of 
phosphodeficient forms of CCND2 increases progenitor proliferation and the proportion of 
cells undergoing mitosis, with a concomitant decrease in the exit fraction.
Lastly, we investigated how transfection of cortical progenitors with WT and mutant 
CCND2 forms would impact the RGC and IPC populations. Previous work has detailed the 
transition of progenitors from Pax6-expressing RGCs to Tbr2-positive IPCs during 
development within the cortex16,17. Therefore, we examined the expression of Pax6 and 
Tbr2 in electroporated progenitors. First, we examined the proportion of electroporated 
progenitors that co-express Pax6. Introduction of the GFP only control generated 21.5 ± 
1.5% of GFP+ cells that were positive for Pax6 as well (Supplementary Fig.3a). 
Electroporation with either the WT CCND2 or the phosphomimetic CCND2 construct did 
not result in an increase in the proportion of progenitors that were immunopositive for Pax6 
(20.1 ± 1.1%, and 23.0 ± 0.6%, respectively). In contrast, electroporation of the 
phosphodeficient CCND2 construct caused a significant increase in the proportion of GFP+ 
progenitors that co-express Pax6, over all other groups (27.7 ± 1.4%), indicating that 
phosphodeficient CCND2 leads to expansion of RGCs in the developing cortex. We then 
found that the GFP only control resulted in 9.4 ± 0.7% of GFP+ cells also expressing Tbr2 
(Supplementary Fig.3b). In contrast, the WT CCND2 sequence and expression of the 
phosphomimetic sequence generated significant increases in the proportion of electroporated 
cells (17.6 ± 2.1%, 15.3 ± 1.7%, respectively) that were also immunopositive for Tbr2, 
signifying an expansion of the IPC population. The phosphodeficient CCND2 mutant 
produced an even greater, 27.4 ± 2.9%, expansion of progenitors expressing both GFP and 
Tbr2, which was significantly different from the GFP control, WT CCND2, and 
phosphomimetic groups. Thus, the phosphodeficient, degradation resistant form of CCND2 
causes an expansion of both the RGC and IPC population. We suggest it is this expansion 
that underlies the megalencephaly in MPPH patients. The WT CCND2 sequence resulted in 
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an increase in the proportion of transfected progenitors that co-express Tbr2, but not Pax6, 
suggesting that WT CCND2 might preferentially promote expansion of the IPC population.
Polymicrogyria in MPPH patients may be related to an altered relationship between basal 
progenitors and radial glia. A homozygous loss of function mutation in EOMES (TBR2), 
expressed in IPCs, was previously associated with a microcephaly-polymicrogyria 
phenotype18. In fetal brain, CCND2 is expressed mostly in IPCs and altered cyclin D2 levels 
are expected to disrupt the proportion of IPC- vs. RGC-derived neurons and/or the 
differentiation program of IPCs14. We note that CCND2-mutated MPPH patients have 
polydactyly more frequently than those with PI3K-AKT pathway mutations (Supplementary 
Table 1), but the mechanism underlying this phenotypic difference remains to be explored.
Thus, we have identified a highly specific pattern of de novo mutations in CCND2 in 12 
subjects with MPPH. We, and others previously reported activating mutations in PI3K-AKT 
pathway elements upstream of CCND2 in other patients with MPPH and overlapping 
megalencephaly syndromes1-3. Evidence presented here supports that these two types of 
mutational events result in a common functional endpoint, namely increased cyclin D2 
activity in neural precursors due to its intracellular accumulation. The data suggest that 
pathological stabilization of cyclin D2 in the developing cerebral cortex may represent a 
unifying mechanism for the development of megalencephaly and polymicrogyria in MPPH 
and other PI3K-AKT associated megalencephaly syndromes (Supplementary Figure 4).
ONLINE METHODS
Whole exome sequencing
Alignment and variant calling (JT144)—Target capture was performed using the 
Agilent SureSelect All Exon v4 exome enrichment kit, according to standard manufacturer 
protocols. Sequencing of 150-bp paired end reads was performed using an Illumina MiSeq. 
Reads were aligned to GRCh37 using Novoalign (Novocraft Technologies, Selangor, 
Malaysia) and processed using the Genome Analysis Toolkit (GATK) and Picard (see 
URLs) to perform realignment of short insertions and deletions (indels) and remove 
duplicate reads. Depth of coverage of the consensus coding sequence (CCDS) was assessed 
using the GATK, which showed that >94 % of CCDS bases were covered by at least five 
good quality reads (minimum Phred-like base quality 17 and minimum mapping quality 20). 
Single nucleotide variants (SNVs) and indel variants were called using the 
UnifiedGenotyper feature of the GATK19,20.
Filtering (JT144)—Custom Perl scripts were used to remove variants present in 
dbSNP132 or with a minor allele frequency ≥ 0.1 % and to annotate functional 
consequences. We identified variants present in the child, but not their parents with a 
minimum Phred-like genotype quality of 30 and selected for indels within coding regions, 
non-synonymous SNVs and splice-site variants. Variants present the 1000 Genomes dataset 
(Nov. 2011), the NHLBI GO exomes and another 22 ethnically matched in-house exomes 
were also removed. This left four de novo variants (CCND2 [NM_001759] c.838A>G, 
p.Thr280Ala; HN1L [NM_144570] c.58C>G, p.Pro20Ala; GLG1 [NM_012201] c.
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1229A>G, p.His410Arg; BTG3 [NM_001130914] c.387del, p.Ala131Argfs*16) which were 
confirmed present in the child and absent in the parents by Sanger sequencing.
Alignment and variant calling (LR11-424 and LR02-064)—Target capture was 
performed using the Agilent SureSelect All Exon 50 MB exome enrichment kit according to 
standard manufacturer protocols. Sequencing of 100-bp paired end reads was performed 
using an Illumina HiSeq 2000, which generated over 13 Gb of sequence for each sample. 
We removed adaptor sequences and quality trimmed reads using the Fastx toolkit (see 
URLs) and then used a custom script to ensure that only read pairs with both mates present 
were subsequently used. Reads were aligned to hg19 with BWA 0.5.921, and indel 
realignment was done using GATK19,20. Duplicate reads were marked using Picard (see 
URLs) and excluded from downstream analyses. We assessed coverage of CCDS bases 
using the GATK, which showed that all samples had >=92.7% of CCDS bases covered by at 
least 10 reads, and >=88.4% of CCDS bases covered by at least 20 reads. SNVs and indels 
were called using samtools mpileup with the extended base alignment quality (BAQ) 
adjustment (-E), and were then quality filtered to require at least 20% of reads supporting 
the variant call22. Variants were annotated using both Annovar23, and custom scripts to 
annotate functional consequences, and whether they had previously been seen in dbSNP132, 
the 1000 Genomes dataset (Nov. 2011), the NHLBI GO exomes or in approximately 570 
exomes previously sequenced at our centres.
Filtering (LR11-424 and LR02-064)—We removed all variants seen in the parents of the 
affected subjects, or in any of our 570 controls samples, the 6500 NHLBI GO exomes or the 
1000 Genomes project. We focused on nonsynonymous SNVs, indels and splice site 
variants. This analysis revealed a single de novo variant, p.Lys270X in CCND2, in patient 
LR11-424. Surprisingly, LR02-064 had the same CCND2 variant, p.Lys270X, which was 
not present in the single parent that was exome sequenced.
Constructs for site-directed mutagenesis and transfection—A C-terminal myc-
tagged cDNA clone of CCND2 transcript NM_001759 was purchased from Origene 
(Origene, Rockville, MD, USA, cat. RC210316). The constructs with p.Thr280Ala, 
p.Pro281Arg or p.Val284Gly mutations were created using the QuikChange Site-Directed 
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) as per manufacturer’ s 
instructions with the primer pairs as in Supplementary Table 4.
Transfection and protein extractions—HEK293 cells were transfected with WT or 
mutant CCND2 constructs using Lipofectamine™ 2000 Transfection Reagent (Life 
Technologies, Paisley, UK) as per the manufacturer’ s instructions. Media was changed 24 
hours post-transfection for media containing 50 μg/ml cycloheximide (Sigma-Aldrich, 
Gillingham, UK) to block protein translation. Protein was extracted at 0, 60, 120 and 240 
minute time points, using NP-40 lysis buffer (150 mM sodium chloride, 1.0% NP-40, 50 
mM Tris, pH 8.0) containing protease and phosphatase inhibitors (Thermo Scientific, 
Loughborough, UK).
Lymphoblastoid cell line treatment and protein extraction—Lymphoblastoid cell 
lines derived from patients with mutations in PIK3R2 (p.Gly373Arg), PIK3CA 
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(p.Glu453del) or AKT3 (p.Arg465Trp) were treated with 25 μg/ml cycloheximide (Sigma-
Aldrich) for 0, 30, 60 or 90 minutes and protein extracted as above.
Western blotting of CCND2-myc construct transfected cell line and patient 
lymphoblastoid protein extracts—Equal amounts of protein were heated to 70°C for 
10 mins with NuPAGE® LDS Sample Buffer (4X) (Life Technologies) and run on 
NuPAGE® Novex® 4-12% Bis-Tris gels (Life Technologies) and transferred to PVDF 
membranes (Life Technologies). Membranes were blocked for one hour at room 
temperature (RT) with 5% dried skimmed milk (Marvel) in PBS with 0.1% Tween-20. 
Membranes were then incubated with primary antibody at a dilution of 1:200 for CCND2 
(ab3085, Abcam, Cambridge, UK) and 1:10,000 for Ś-actin (ab8226, Abcam) overnight in 
blocking solution at 4°C with slight agitation. The membranes were washed with 0.1% 
Tween-20 in PBS and then incubated with secondary antibody for 1 hour at RT. The 
secondary antibody (polyclonal goat anti-mouse immunoglobulins/HRP, P0447, Dako, Ely 
UK) was diluted 1:10,000 in blocking solution. Membranes were then washed in PBS with 
0.1% Tween-20, developed with SuperSignal West Femto Chemiluminescent Substrate 
(Thermo Scientific) and visualized using a Geldoc XR system (Biorad, Hemel Hempstead, 
UK). Experiments were performed in triplicate and .tiff images were analyzed using 
ImageJ24. Bands were quantified and intensities determined relative to the corresponding ‘ 0’  
time point. CCND2 intensity was normalized with Ś-actin.
Generation of constructs for in utero electroporation—The open reading frame of 
human CCND2 was cloned into the pCAGIG vector (IRES-eGFP, Addgene, Cambridge, 
MA, USA) at the multiple cloning site following digestion with EcoRI and XhoI. 
Phosphodeficient (p.Thr280Ala), phosphomimetic (p.Thr280Asp) and patient (p.Pro281Arg) 
mutations were made using the QuikChange Site-Directed Mutagenesis Kit (Supplementary 
Table 4; Agilent Technologies, Santa Clara, CA, USA) as per manufacturer’ s instructions. 
The p.280 phosphodeficient mutation involved the following change: ACC (Thr) to GCC 
(Ala), the phosphomimetic mutation entailed altering the first mutant: GCC (Ala) to GAC 
(Asp) and the p.281 mutation changed CCT (Pro) to CGT (Arg). Constructs were then 
sequenced to confirm the mutations. There were five experimental groups: GFP control, WT 
CCND2, p.Thr280Ala, p.Thr280Asp, and p.Pro281Arg CCND2 mutants.
Animals—Timed pregnant female wild-type CD-1 mice at least 10 weeks of age were 
obtained from Charles River Laboratories (Wilmington, MA, USA) and then maintained as 
part of our laboratory colony and were housed at 23°C with a 12h light/dark cycle in Thoren 
units. The day of plug discovery (at 12 noon) was designated as embryonic day 0.5 (E0.5). 
All experiments were performed in accordance with protocols approved by the Weill 
Cornell Medical College Institutional Animal Care and Use Committee.
In utero electroporation and BrdU injections—Electroporations were carried out at 
E13.5. The pregnant dam was anesthetized with Isoflurane (Butler Schein, Dublin, OH, 
USA) and a laparotomy was performed to expose the uterus. DNA was diluted 1:20 in Fast 
Green (Sigma-Aldrich) to achieve a final concentration of 1 μg/μl. Then, 1 μg DNA was 
injected into the lateral ventricle of each embryo. Tweezertrodes (7 mm platinum, BTX, 
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Harvard Apparatus, Holliston, MA, USA) were placed over the injection site and then five 
50-ms pulses at 42 V were delivered with 1-s intervals between each pulse using a BTX-
ECM830 electroporator (BTX, Harvard Apparatus) to introduce DNA into the cortex. 
Embryos were returned to the abdominal cavity, the wound was sutured; dams were allowed 
to recover and were closely monitored. Embryos were harvested at 48 hours post-IUEP at 
E15.5. Embryo brains were collected in cold 1x phosphate buffered saline (PBS) and 
screened for GFP expression using a stereomicroscope (Leica M165 FC, Buffalo Grove, IL, 
USA). Brains were transferred to 4% paraformaldehyde in 1x PBS with 7% sucrose 
overnight at 4°C. The following day, brains were transferred to 15% sucrose and then 30% 
sucrose in 1x PBS, shaking at 4°C, until properly sunk. Brains were then embedded in 
optimal cutting temperature solution (Electron Microscopy Sciences, Hatfield, PA, USA) 
and stored at −20°C.
A subset of pregnant dams were injected with bromodeoxyuridine (BrdU; Sigma-Aldrich, 
St. Louis, MO, USA) at 50 mg/kg at E14.5 (24 hours post-IUEP). All tissue was then 
harvested at E15.5 (48 hours post-IUEP).
Immunohistochemistry—Brains were sectioned coronally at 12 μm on a cryostat 
(HM505E, Microm, Mars, PA, USA) and collected on glass slides. Sections to be stained 
were washed 3x with 1x PBS with 0.3% Triton X-100 (PBS-T) and then subjected to 
antigen retrieval with steam in 1 mM EDTA, 5 mM Tris pH 8 (GFP and Pax6 dual labeling) 
for 20 mins or 10 mM sodium citrate buffer, pH 6 for 15 mins (for all other staining). Slides 
were allowed to come to RT, rinsed in 1x PBS-T, and then blocked for 1 h at RT in 10% 
normal donkey serum (Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA) 
in 1x PBS-T. Antibodies were diluted in blocking medium and were used as follows: anti-
GFP (600-101-215, goat IgG, Rockland Immunochemicals, Inc., Gilbertsville, PA, USA, 
1:10,000), anti-Ki67 (RM-9106-S1, rabbit IgG, Thermo Scientific, Waltham, MA, USA, 
1:1000), anti-phosphohistone H3 (PH3, 06-570, rabbit IgG, Millipore, Billerica, MA, USA, 
1:2000), anti-BrdU, 555627, mouse IgG, BD Biosciences, San Jose, CA, USA, 1:500), anti-
Pax6 (PRB-278P, rabbit IgG, Covance, Princeton, NJ, USA, 1:1000), and anti-Tbr2 
(ab23345, rabbit IgG, Abcam, 1:2000). Primary antibodies were incubated overnight at 4°C. 
The following day, slides were washed 3x in 1x PBS-T and incubated with Alexa 
fluorescence-conjugated secondary antibodies (Molecular Probes, Life Technologies, Grand 
Island, NY, USA, 1:1000 in blocking solution) for 2 h at RT. Slides were then washed and 
coverslipped with ProLong Antifade Kit (Life Technologies).
An additional set of brains was processed for paraffin sectioning as previously described14. 
Sections were collected at 4 μm and first processed for anti-CCND2 immunohistochemistry 
(MS-221-P0, mouse IgG, Thermo Scientific, 1:100)14. After the primary antibody 
incubations, sections were incubated in biotinylated secondary antibody (1:400, 1 hr), and 
then peroxidase-conjugated tertiary antibody for 1 hr following manufacturer’ s instructions 
(Covance). Tissue was then subjected to a 3,3-diaminobenzidine (DAB) reaction (Covance). 
Next, tissue was thoroughly washed and then blocked, and incubated with anti-GFP 
antibodies (as above, 1:500) overnight. Fluorescent secondary antibody incubations were 
carried out as described above.
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Microscopy and Cell Quantifications—Sections were imaged with a 20x objective 
using an epifluorescent microscope (Leica DM550B with Leica Application Suite Advanced 
Fluorescence 3.0.0 build 8134 software, Leica Microsystems Inc., Buffalo Grove, IL, USA). 
Sections through the entire electroporated area (rostro-caudal) were analyzed. Embryos that 
expressed GFP through the cortex were analyzed. Those that did not fit these criteria were 
eliminated from analyses and all embryos that met these criteria were quantified. For all 
IUEP experiments, embryo brains were assigned a random number that the investigator 
performing the counts was not privy to, so as to reduce bias. After the counts were 
completed, embryos were matched to their respective numbers and assigned to appropriate 
experimental groups.
The number of total GFP+ cells and the number of GFP+/Ki67+ cells were counted and 
computed so that n=# of embryos, five sections/embryo (n=7 GFP, n=5 WT CCND2, n=5 
p.Thr280Ala, n=5 p.Thr280Asp, and n=5 p.Pro281Arg. At least 7000 GFP+ cells were 
analyzed for each experimental group. For the GFP/PH3 co-labeling experiment, at least 
5300 GFP+ cells/experimental group were analyzed (n=4 WT CCND2, n=5 p.Thr280Ala, 
and n=5 p.Thr280Asp, 5 sections/embryo). Lastly, for the GFP/BrdU/Ki67 experiment, at 
least 6800 GFP+ cells were analyzed/group (n=5 WT CCND2, n=5 p.Thr280Ala and n=5 
p.Thr280Asp, 5 sections/embryo). To calculate the P-Fraction (proliferative fraction) and 
exit fractions we employed the following formulas:
P-Fraction: (total number of GFP+/BrdU+/Ki67+ cells)/(total number of GFP+/BrdU+ 
cells) × 100
Exit fraction: (total number of GFP+/BrdU+ cells) − (total number of GFP+/BrdU+/Ki67+ 
cells)/(total number of GFP+/BrdU+ cells) × 100
For the GFP/Pax6 analysis, at least 8500 GFP+ cells/experimental group were counted (n=6 
GFP, n=8 WT CCND2, n=5 p.Thr280Ala, and n=5 p.Thr280Asp, 5 sections/embryo). 
Lastly, for the GFP/Tbr2 experiment, at least 6400 GFP+ cells/experimental group were 
counted (n=6 GFP, n=6 WT CCND2, n=5 p.Thr280Ala, and n=5 p.Thr280Asp, 5 sections/
embryo).
Final counts are presented as percentages ± standard error measurement. Unless otherwise 
noted, a two-tailed unpaired Student’ s t-test was performed with a p< 0.05 considered 
significant. For Figure 4 and the Pax6 and Tbr2 experiments (Supplementary Figure 3), a 
one-way ANOVA was used where a p <0.05 was deemed significant. Post hoc tests (LSD) 
were then performed to corroborate the independent t-tests. Pairwise comparisons were not 
adjusted for the multiple comparisons because all groups were defined a priori. In this case, 
the statistical values shown were from the post hoc tests following an ANOVA analysis. 
Statistics were calculated using Microsoft Excel and SPSS (Version 22, IBM). All analyzed 
data met the assumptions of the two-tailed unpaired Student’ s t-test or the one-way ANOVA 
and the variance between experimental groups was similar. For all in utero experiments, we 
estimated we would need 4-7 embryos/group based on studies previously performed in our 
laboratory13. Graphs were made in Microsoft Excel and final figures were compiled in 
Adobe Photoshop 12.0 (Adobe Systems, San Jose, CA, USA).
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Cell Culture—HEK293 cells (from ATCC) were transfected with the IUEP constructs 
using XFect (Clonetech Laboratories Inc., Mountain View, CA, USA) according to 
manufacturer’ s instructions and then collected 48 hrs later. Cells were lysed using 
Mammalian Protein Extraction Reagent (Thermo Scientific) with protease and phosphatase 
inhibitors in addition to EDTA and then flash frozen until needed for western blotting.
Western blotting of GFP constructs—Samples were reduced and boiled at 70°C for 
10 minutes. Equal amounts of protein were run on polyacrylamide gels as above 
(Invitrogen) and then transferred to nitrocellulose membranes (Whatman, Piscataway, NJ, 
USA). Membranes to be stained with anti-CCND2 and anti-GFP antibodies were blocked in 
5% non-fat dry milk in 1x Tris-buffered saline with 0.05% Tween 20 (TBS-T). Membranes 
were then incubated in primary antibodies as follows: anti-CCND2 (sc-53637/sc-56305, 
mouse IgG, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, 1:1000) and anti-GFP 
(see above, goat IgG, 1:4,000), diluted in block solution overnight at 4°C with slight 
agitation. The following day, membranes were washed and then incubated in secondary 
antibody for 1 hr at RT diluted in Odyssey LI-COR solution with 0.05% Tween 20 using LI-
COR secondary antibodies (1:10,000, donkey anti-mouse IRDye 800SCW and donkey anti-
goat IRDye 680LT). Blots were then visualized on the Odyssey FC imaging system (LI-
COR Biosciences, Lincoln, Nebraska, USA). Quantitation was determined by serial dilution 
of lysates and fluorescent values within the linear range were used for determining relative 
levels, normalized to the loading control of total GSK-3Ś. Primary antibodies used in the 
quantitative westerns included anti-CCND2 (as above), anti-CCND1 (ab134175, rabbit IgG, 
Abcam, 1:4000), anti-GSK-3Ś(9832, mouse IgG, Cell Signaling, Danvers, MA, USA, 
1:2000), and anti-pS9-GSK-3Ś(9323, rabbit IgG, Cell Signaling, 1:1000).
Western blotting of AKT3-D219V embryo brain lysates—Embryo brains were 
harvested at E14.5. Lysates were prepared and equal amounts of protein were loaded onto 
polyacryl-amide gels for Western blot transfer and immunodetection as for cell cultures 
above. A total of three WT/Akt3-D219V/D219V littermate pairs were analyzed, providing 
three biological replicates. Each WT/Akt3-D219V/D219V pair was processed in parallel as 
follows: 21, 18, 15, 12, 9 or 6 μl of lysate was loaded on a gel. Out of 6 data points for each 
biological replicate at least three were in the linear range, giving three technical replicates 
for each sample, for a total n=9. WT and mutants were then compared using a sign test and 
for every WT-mutant pair from the same litter and of the same dilution the sign of the 
difference was the same (e.g. CCND2 or CCND1 was greater in the mutant than WT 
littermate), for a two-sided level of significance of 0.02.
URLs—FASTX-Toolkit, http://hannonlab.cshl.edu/fastx_toolkit/; GATK, http://
www.broadinstitute.org/gsa/wiki/; Picard tools, http://picard.sourceforge.net/; Samtools, 
http://samtools.sourceforge.net/, Homologene, http://www.ncbi.nlm.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Images of children with MPPH and CCND2 mutations. Photos and brain MRI of 4 affected 
individuals are shown: (a-d) LR07-041, (e-h) LR02-064, (i-l) JT-144, and (m-p) JT-210. (a, 
e, i, m, n) Photographs demonstrate macrocephaly with prominent forehead, and (b, f, j) 
postaxial polydactyly of the hands. (c, g, k, o) T1- or T2-weighted midsagittal images 
demonstrate large brain size in relation to facial structures, (d, h, l, p) while axial images 
show polymicrogyria that appears most severe in the perisylvian regions, but also involves 
other regions. All patients gave informed consent for publication.
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Figure 2. 
Cyclin D2 (CCND2) mutations and protein conservation. Schematic showing the intron/
exon structure of human CCND2. The cDNA sequence from c.805 and corresponding 
peptide sequence from p.S269 are shown with positions mutated in MPPH subjects marked 
in red. See also Supplementary Figure 1.
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Figure 3. 
Cyclin D2 (CCND2) protein stabilization by MPPH mutations. (a) Representative blots 
from CCND2 transfection experiments. Protein extracts from HEK293 cells transfected with 
WT or mutant CCND2 treated with cycloheximide (CHX) at time point 0 were analyzed by 
western blotting with an antibody against CCND2. WT CCND2 constructs demonstrate a 
drop in protein levels following inhibition of protein translation by CHX, while mutant 
constructs show apparently stable levels of the protein. (b) Quantification of CCND2 protein 
levels in transfected HEK293 cells as a proportion of Ś-actin levels averaged over three 
experiments. Relative densities of bands were determined relative to 1 at time point 0 for 
each experiment and normalized using the Ś-actin loading control. (c) Representative blots 
from patient lymphoblastoid experiments. Protein extracts from lymphoblastoid cells treated 
with CHX were subjected to Western blotting using an anti-CCND2 antibody. Control cells 
show a decline of endogenous CCND2 following CHX treatment while cells from patients 
with mutations in PI3K-AKT pathway genes previously implicated in MCAP/MPPH appear 
to maintain relatively stable levels of the protein. (d) Quantification of CCND2 protein 
levels in lymphoblastoid cell lines as a proportion of Ś-actin levels averaged over three 
experiments. Relative densities of bands were determined relative to 1 at time point 0 for 
each experiment and normalized using a Ś-actin loading control. Mean values and standard 
error bars are shown * p< 0.05, ** p<0.01, *** p< 0.0001 (e) Quantitative western blot of 
E14.5 brain from embryos homozygous for constitutively active Akt3-D219V shows equal 
Mirzaa et al. Page 16
Nat Genet. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
loading of total GSK-3Ś, but elevated pS9GSK-3Ś and CCND2 levels. Mean values and 
standard error bars are shown, *p<0.05.
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Figure 4. 
Comparative ability of mutant and WT cyclin D2 (CCND2) to enhance neural progenitor 
proliferation in embryonic mouse brain. Two patient mutations (p.Thr280Ala and 
p.Pro281Arg) are compared to WT and phosphomimetic (p.Thr280Asp) CCND2. WT and 
mutant cDNAs were cloned into an IRES eGFP vector affording independent translation of 
both CCND2 and, from an internal ribosome entry site, eGFP. Electroporated (GFP+) cells 
expressed either GFP alone or together with human WT or mutant CCND2. Constructs (1 μg 
each) were delivered to cortex by IUEP at E13.5 and embryos were harvested at E15.5. (a-e) 
Cortical sections were immunostained with an anti-GFP antibody. (f-j) The same sections 
were double immunolabeled (yellow) with anti-GFP (green) and proliferation marker, anti-
Ki67 (red), antibodies. (a,f) Cells receiving vector without CCND2 are mostly no longer 
dividing and many have migrated up to the cortical plate. (b,g) More cells continue to divide 
(yellow cells, mostly in the SVZ/IZ) when overexpressing WT CCND2. (c,h,e,j) Progenitors 
expressing the phosphodeficient p.Thr280Ala or putative phosphodeficient p.Pro281Arg 
CCND2 found in MPPH patients show strikingly more proliferation and fewer GFP+ cells 
residing in the cortical plate. (d,i) A phosphomimetic (p.Thr280Asp) form of CCND2 is 
significantly less effective in promoting proliferation than the patient mutations. (k) 
Quantification of the proportions of transfected (GFP+) cells that are proliferating (GFP
+Ki67+/GFP+ total cells) *p<0.05, **p<0.001 with respect to GFP-only (control); 
§p<0.0001 with respect to WT-CCND2 or p.Thr280Asp as indicated. Full statistical 
summary is shown in Supplementary Table 2. n=7 embryos (a), n=5 embryos each (b-e), 
n=embryos, each value average of 5 sections/embryo. MZ=marginal zone, CP=cortical 
plate, IZ=intermediate zone, SVZ=subventricular zone, VZ=ventricular zone. Scale bar = 20 
μm.
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Figure 5. 
Phosphodeficient CCND2 more effectively promotes proliferation and prevents neural 
progenitor cells from exiting the cell cycle. (a-d) Tissue sections immunostained with anti-
GFP (green) and anti-PH3 (purple) antibodies following electroporation with WT, 
phosphodeficient (p.Thr280Ala), and phosphomimetic (p.Thr280Asp) CCND2. (a,b) 
Compared to WT CCND2 introduction of the phosphodeficient CCND2 resulted in a 
significant increase in the number of GFP+ and PH3+ double-labeled cells in the VZ/SVZ, 
(c) while the phosphomimetic CCND2 was no different from WT. (d) Quantification shows 
significantly more GFP+ PH3+ cells after introduction of phosphodeficient CCND2 
compared to the WT (p=0.000054) or phosphomimetic sequences (p=0.00049). There was 
no difference between the phosphomimetic and WT CCND2 forms (p=0.41). (e-l) 
Comparison of actively proliferating (P-Fraction) and non-proliferating (Exit Fraction) 
cortical progenitors transfected with WT or mutant CCND2 constructs. (e-g) Cells were co-
labeled with anti-GFP (green) and anti-BrdU (red) antibodies following BrdU injection at 
E14.5 (24 hours post-IUEP) and harvest at E15.5. (h-j) The same samples were also co-
labeled with anti-Ki67 (blue) antibodies. (e,h,k) Expression of either the WT or (g,j,k) 
phosphomimetic (p.Thr280Asp) forms of CCND2 resulted in a similar increase in the 
percentage of progenitors in the exit fraction over the P-fraction (see Methods for 
calculations), thereby indicating more cells had exited the cell cycle 24 hours post-BrdU 
injection. (f,i,k) Introduction of the phosphodeficient (p.Thr280Ala) form of CCND2 
significantly increased the number of progenitors in the P-fraction (still proliferating 24 
hours post-BrdU pulse) and correspondingly decreased the exit fraction, compared to both 
the WT and phosphomimetic forms of CCND2. Thus, phosphodeficient CCND2 was more 
effective in promoting mitotic events and keeping cells in cycle. Full statistical analyses are 
in Supplementary Table 3. GFP/PH3 experiment, n=4 WT CCND2, n=5 p.Thr280Ala, and 
n=5 p.Thr280Asp. GFP/BrdU/Ki67 experiment, n=5 WT CCND2, n=5 p.Thr280Ala, and 
n=5 p.Thr280Asp. n=embryos, each value average of 5 sections/embryo. Data are presented 
as mean ± standard error measurement. MZ=marginal zone, CP=cortical plate, 
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IZ=intermediate zone, SVZ=subventricular zone, VZ=ventricular zone. Scale bar in (c) and 
(j) = 20 μm. *p<0.02 compared to WT CCND2, and §p<0.01 compared to p.Thr280Ala.
Mirzaa et al. Page 20
Nat Genet. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
M
irzaa et al.
Page 21
Table 1
Summary of the phenotypic and molecular data of 12 MPPH individuals with CCND2 mutations
Subject ID Sex Age last
assessed
OFC
HYD or
VMEG
Shunt, age
at shunting PMG** Polydactyly§ ID
cDNA
change
Amino-acid
change InheritanceFirst OFC
SD (age)
Last OFC
SD (age)
LR02-064* F 6y +3 (5days) +3 (6y) HYD +, 6y BPP grade 1 ++/++ Severe, nolanguage c.808A>T p.Lys270X de novo
LR11-424* F 18m +4 (birth) +4 (18m) VMEG – BPP grade 2 +−/++ Severe c.808A>T p.Lys270X de novo
JT-144a* F 3y +3 (birth) +2.5 (3y) VMEG – BPP grade 2 ++/++ Severe, nolanguage c.838A>G p.Thr280Ala de novo
VI13216 M 7y +4 (birth) +7.5 (7y) VMEG – BPP grade 1 ++/−− Severe .838A>G p.Thr280Ala de novo
LR07-041b F 8m +4 (6w) +2 (8m) VMEG(mild) – BPP grade 1 ++/−−
Severe, no
language c.839C>A p.Thr280Asn de novo
LR11-352c F 13y +4.5 (2w) +5 (13y) VMEG – BPP grade 2 ++/++ Mild LD,
ambulatory c. 839C>A p.Thr280Asn de novo
JT-232 M 5y +3.5(2days) +6 (5y) VMEG – BPP grade 2 −−/++
Severe, no
language c.839C>A p.Thr280Asn Parents NA
LR11-346d F 28wkgestation MEG
b NA VMEG(mild) –
Frontoparieta
l PMG ++/−− NA c.841C>T p.Pro281Ser de novo
LP95-025 F 20y + 4 (3y) +2.5 (8y) HYD +, 1m BPP grade 2 −−/−− Severe, nolanguage c.842C>G p.Pro281Arg de novo
JT-210e F 2y +2 (birth) +2 (2y) VMEG(mild) – BPP grade 2 ++/−+ Severe c.842C>G p.Pro281Arg
Mother negative,
father NA
LR03-260 M 9y +2 (birth) +5 (9y) VMEG – BPP grade 1 ++/++ Severe c.842C>T p.Pro281Leu SupplementaryNote
JT-238 F 11y +2.5 (birth) +3.5 (11y) VMEG(L>R) – BPP grade 1 ++/++ Severe c.851T>G p.Val284Gly
Mother negative,
father NA
Abbreviations: BPP, bilateral perisylvian polymicrogyria; F, female; HYD, hydrocephalus; ID, intellectual disability; LD, learning disability, m, months; M, male; MEG, megalencephaly; NA, not 
available/not applicable; OFC, occipitofrontal circumference; PMG, polymicrogyria; SD, standard deviations; VMEG, ventriculomegaly; w, weeks; y, years.
*Subjects analyzed by exome sequencing. Mutation locations are based on reference gene accession NM_001759 (CCND2). All mutations were absent from the Exome Variant Server, which consists of 
whole-exome sequencing data from 6500 subjects (accessed January 2012).
**
Bilateral perisylvian polymicrogyria (BPP) grades: grade 1, PMG extending beyond the perisylvian regions to the frontal or occipital poles or both; grade 2, PMG extending beyond the perisylvian 
regions but not to either pole
§
Postaxial polydactyly: both hands / both feet
Additional phenotype information:
Nat G
enet
.
 A
uthor m
anuscript; available in PM
C 2014 N
ovem
ber 01.
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
M
irzaa et al.
Page 22
aJT-144: this child’ s non-identical twin sister is healthy.
b
LR07-041: this child had progressively worsening irritability, severe episodes of opisthotonus, Cheyne-Stokes respirations, poor eye contact, and died at 8 months of age.
c
LR11-352: this child walked unassisted at 5 years. Her speech is limited to 2-word phrases.
d
LR11-346: this pregnancy was terminated at 28 weeks of gestation. On autopsy examination, the brain weighed 3x the normal weight.
eJT-210: this child has cortical visual blindness and a ventricular septal defect that closed spontaneously
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